Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
39.04 USD | +0.15% | -1.55% | +152.67% |
Valuation
Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|
Capitalization 1 | 568.5 | 535.2 | 683.4 | 2,132 | - | - |
Enterprise Value (EV) 1 | 568.5 | 535.2 | 683.4 | 2,132 | 2,132 | 2,132 |
P/E ratio | -11 x | -5.78 x | -6.84 x | -17 x | -16 x | -15.9 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | 62.5 x |
EV / Revenue | - | - | - | - | - | 62.5 x |
EV / EBITDA | - | -5.94 x | -6.98 x | -16 x | -13.8 x | - |
EV / FCF | -24 x | -7.91 x | -7.41 x | -19.7 x | -15.7 x | -16.6 x |
FCF Yield | -4.17% | -12.6% | -13.5% | -5.07% | -6.38% | -6.01% |
Price to Book | - | 6.99 x | 6.72 x | 4.99 x | 5.71 x | - |
Nbr of stocks (in thousands) | 21,278 | 27,658 | 44,433 | 54,701 | - | - |
Reference price 2 | 26.72 | 19.35 | 15.38 | 38.98 | 38.98 | 38.98 |
Announcement Date | 3/28/22 | 3/28/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | 34.11 |
EBITDA 1 | - | - | -90.06 | -97.93 | -133 | -154 | - |
EBIT 1 | - | -34.4 | -90.9 | -102 | -128.6 | -144.5 | -149.9 |
Operating Margin | - | - | - | - | - | - | -439.41% |
Earnings before Tax (EBT) 1 | - | -32.61 | -89.06 | -95.99 | -123.6 | -141.7 | -149.8 |
Net income 1 | -53.41 | -32.61 | -89.06 | -95.99 | -123.6 | -139.1 | -147.1 |
Net margin | - | - | - | - | - | - | -431.32% |
EPS 2 | -14.40 | -2.430 | -3.350 | -2.250 | -2.290 | -2.444 | -2.447 |
Free Cash Flow 1 | - | -23.71 | -67.66 | -92.24 | -108 | -136.1 | -128.2 |
FCF margin | - | - | - | - | - | - | -375.75% |
FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - | - |
Announcement Date | 3/19/21 | 3/28/22 | 3/28/23 | 3/20/24 | - | - | - |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA 1 | - | - | -15.16 | -25.4 | -32.98 | -31.76 | -22.94 | - | -25.86 | -29.64 | -32 | -34 | -35 | - | - |
EBIT 1 | -16.58 | -17.02 | -15.06 | -25.24 | -33.58 | -31.26 | -21.97 | -21.76 | -27.03 | -31.11 | -31.25 | -32.53 | -33.99 | -39.83 | -42.22 |
Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -16.85 | -17.08 | -14.85 | -24.68 | -32.44 | -30.07 | -20.16 | -20.1 | -25.65 | -28.38 | -30.39 | -31.56 | -33.29 | -37.37 | -40.28 |
Net income 1 | -16.85 | -17.08 | -14.85 | -24.68 | -32.44 | -30.07 | -20.16 | -20.1 | -25.66 | -28.38 | -30.39 | -31.56 | -33.29 | -37.37 | -40.28 |
Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EPS 2 | -0.9700 | -0.7100 | -0.5500 | -0.9100 | -1.190 | -0.8000 | -0.4600 | -0.4500 | -0.5800 | -0.5600 | -0.5600 | -0.5775 | -0.5925 | -0.6233 | -0.6267 |
Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Announcement Date | 3/28/22 | 5/16/22 | 8/10/22 | 11/9/22 | 3/28/23 | 5/11/23 | 8/10/23 | 11/9/23 | 3/20/24 | 5/9/24 | - | - | - | - | - |
Balance Sheet Analysis
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Net Debt | - | - | - | - | - | - | - |
Net Cash position | - | - | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | - | - | - |
Free Cash Flow 1 | - | -23.7 | -67.7 | -92.2 | -108 | -136 | -128 |
ROE (net income / shareholders' equity) | - | - | -122% | -107% | -43.8% | -36.1% | - |
ROA (Net income/ Total Assets) | - | - | -82.8% | -62.5% | -41% | -34.6% | - |
Assets 1 | - | - | 107.6 | 153.5 | 301.5 | 402.1 | - |
Book Value Per Share 2 | - | - | 2.770 | 2.290 | 7.810 | 6.830 | - |
Cash Flow per Share | - | - | - | - | - | - | - |
Capex 1 | - | - | - | 0.06 | 0.1 | 0.12 | 0.12 |
Capex / Sales | - | - | - | - | - | - | 0.36% |
Announcement Date | 3/19/21 | 3/28/22 | 3/28/23 | 3/20/24 | - | - | - |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+152.67% | 2.13B | |
+48.86% | 56.95B | |
+39.98% | 40.26B | |
-7.00% | 39.32B | |
-4.42% | 28.37B | |
+12.17% | 26.45B | |
-17.96% | 19.41B | |
+29.22% | 12.54B | |
+25.64% | 12.21B | |
-0.30% | 12.15B |
- Stock Market
- Equities
- VERA Stock
- Financials Vera Therapeutics, Inc.